---
title: "MediWound Reports Second Quarter 2026 Financial Results and Provides Corporate Update"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295789269.md"
description: "The Phase III VALUE trial for EscharEx® is currently progressing, with an anticipated interim assessment and completion of enrollment by the end of the first quarter of 2027. This trial is a significant step in the development of EscharEx®, a potential medical treatment. Stay tuned for updates as we move closer to these important milestones."
datetime: "2026-08-13T11:06:23.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295789269.md)
  - [en](https://longbridge.com/en/news/295789269.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295789269.md)
generator: "portal-rs"
---

# MediWound Reports Second Quarter 2026 Financial Results and Provides Corporate Update

The Phase III VALUE trial for EscharEx® is currently progressing, with an anticipated interim assessment and completion of enrollment by the end of the first quarter of 2027. This trial is a significant step in the development of EscharEx®, a potential medical treatment. Stay tuned for updates as we move closer to these important milestones.

### Related Stocks

- [MDWD.US](https://longbridge.com/en/quote/MDWD.US.md)

## Related News & Research

- [Analysts Offer Insights on Healthcare Companies: Mediwound (MDWD) and Capricor Therapeutics (CAPR)](https://longbridge.com/en/news/296009139.md)
- [MediWound Ltd. (NASDAQ:MDWD) Just Released Its Second-Quarter Results And Analysts Are Updating Their Estimates](https://longbridge.com/en/news/296027865.md)
- [MediWound posts investor presentation on enzymatic burn and chronic-wound therapies NexoBrid, EscharEx](https://longbridge.com/en/news/295787062.md)
- [Asker Healthcare Group buys Baltic medtech distributor Ambercell Solutions](https://longbridge.com/en/news/296306272.md)
- [MediWound (NASDAQ:MDWD) Issues Earnings Results](https://longbridge.com/en/news/295866831.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**